陸哲明，北京大學腫瘤醫院， 生化與分子生物學研究室， 教授，研究員，主任
基本介紹
- 中文名：陸哲明
- 國籍：中國
- 民族：漢族
- 職稱：研究員
人物經歷,研究方向,主要成就,社會任職,
人物經歷
2004.9.14～2006.6.14 Harvard University,Harvard Medical School博士後
2006.7.14～2008.4.14 Duke University,Medical Center博士後
2008.5.6～2010.9.6 北京大學腫瘤醫院 助理研究員
2010.10.4～2018.7.31 北京大學腫瘤醫院 副研究員
2018.8.1至今 北京大學腫瘤醫院 研究員
2022.8.1至今 北京大學腫瘤醫院 教授
研究方向
腫瘤個體化免疫治療
主要成就
近五年代表作（第一/責任作者）
Chaoting Zhang#, Yizhe Sun#,Shance Li, Luyan Shen, Xia Teng, Yefei Xiao, Nan Wu*, Zheming Lu* Autophagicflux restoration enhances the antitumour efficacy of tumour infiltratinglymphocytes. Journal for ImmunoTherapy of Cancer. 2022 Oct;10(10):e004868
Luyan Shen#, Yefei Xiao#, Chaoting Zhang, Shance Li, Xia Teng, Likun Cui, Ting Liu, Nan Wu*, Zheming Lu*. Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity. Cancer Letters 2022 Jul 10;538:215710
Luyan Shen, Yefei Xiao, Jiahe Tian, Zheming Lu*. Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy. Cancer Letters 2022 Mar 31;529:139-152.
Chaoting Zhang#, Yizhe Sun#,Shance Li, Luyan Shen, Xia Teng, Yefei Xiao, Ping Zhou*, Zheming Lu* Autophagicflux restoration of senescent T cells improves antitumor activity of TCR-engineered T cells. Clin Transl Immunology. 2022 Sep 26;11(9):e1419.
Hui Liu#, Wen Lei#, Chaoting Zhang#, Chunmei Yang,Juying Wei, Qunyi Guo, Xiaojun Guo, Zhilu Chen, Ying Lu, Ken H Young*, ZhemingLu*, Wenbin Qian*. CD19-Specific CAR-T Cells that Express a PD-1/CD28 ChimericSwitch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma. Clin Cancer Res. 2021 Jan 15;27(2):473-484.
Chaoting Zhang#, Qin Tan#, Shance Li#, Luyan Shen,Jingtao Zhang, Ying Liu, Wenjun Yang*, Zheming Lu*. Induction of EBV latentmembrane protein-2A (LMP2A) specific T cells and construction of individualizedTCR-engineered T cells for EBV associated malignancies. J Immunother Cancer.2021 Jul;9(7):e002516.
Liang Yun#，Liu Hui#，Lu Zheming#, Lei Wen, Zhang Chaoting, Li Ping, Liang Aibin*, Young Ken H*, Qian Wenbin*. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies. J Hematol Oncol. 2021 Feb 16;14(1):26
Chaoting Zhang#, HeyilimuPalashati#, Zhuona Rong, Ningjing Lin, Luyan Shen, Ying Liu, Shance Li, BentongYu*, Wenjun Yang*, Zheming Lu*. Pre-depletion of TRBC1+ T cells promotes thetherapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies. Molecular Cancer 2020, 19:162
Tan Qin, Zhang Chaoting*, Yang Wenjun, Liu Ying,Heyilimu Palashati, Feng Dongdong, Xing Liying, Ke Yang*, Lu Zheming*. Isolationof T cell receptor specifically reactive with autologous tumour cells fromtumour-infiltrating lymphocytes and construction of T cell receptor engineeredT cells for esophageal squamous cell carcinoma. Journal for ImmunoTherapy of Cancer 2019 Aug 28;7(1):232.
Zhang Chaoting#, Ding Huirong#,Huang Hongying, Heyilimu Palashati, Miao Yu, Xiong Hongchao*, Lu Zheming*. TCR repertoire intratumor heterogeneity of CD4+ and CD8+ T cells in centers andmargins of localized lung adenocarcinomas. Int J Cancer. 2019 Feb15;144(4):818-827.
社會任職
- 中華抗癌學會病因學分會常委
- 中國醫藥質量管理協會細胞治療質量控制與研究專業委員會委員
